(Q52533093)

2 May 2018

review article

1 reference

title

Effects of lipids and lipoproteins on thrombosis and rheology. (English)

1 reference

2 May 2018

0 references

0 references

1 reference

Rosenson RS

1

1 reference

2 May 2018

Lowe GD

series ordinal

2

1 reference

2 May 2018

publication date

1 October 1998

1 reference

2 May 2018

published in

Atherosclerosis

1 reference

2 May 2018

volume

140

1 reference

2 May 2018

issue

2

1 reference

2 May 2018

page(s)

271-280

1 reference

2 May 2018

Molecular bases of the acute coronary syndromes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Stability and instability: two faces of coronary atherosclerosis. The Paul Dudley White Lecture 1995.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Coronary plaque erosion without rupture into a lipid core. A frequent cause of coronary thrombosis in sudden coronary death

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Coronary Plaque Disruption

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Characterization of the relative thrombogenicity of atherosclerotic plaque components: Implications for consequences of plaque rupture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Specific platelet mediators and unstable coronary artery lesions. Experimental evidence and potential clinical implications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Are we mortgaging the medical profession?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Identification of active tissue factor in human coronary atheroma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

The possible role of hemorheology in atherothrombogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Enhanced in vivo platelet release reaction and malondialdehyde formation in patients with hyperlipidemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Platelet function in hyperlipoproteinemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Platelet function and survival in patients wit severe hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Increased fibrinogen binding to platelets from patients with familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Platelet membrane glycoproteins: functions in cellular interactions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Vitronectin binds to activated human platelets and plays a role in platelet aggregation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Low-density lipoproteins inhibit the Na+/H+ antiport in human platelets. A novel mechanism enhancing platelet activity in hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Ischemic heart disease and platelet aggregation. The Caerphilly Collaborative Heart Disease Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Intracellular mechanisms in the activation of human platelets by low-density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasma lipoproteins mediate platelet adhesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Platelet interaction with high and low density lipoproteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Prostaglandin I2 half-life regulated by high density lipoprotein is decreased in acute myocardial infarction and unstable angina pectoris

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Vastatins Inhibit Tissue Factor in Cultured Human Macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasma high density lipoproteins inhibit the activation of coagulation factor X by factor VIIa and tissue factor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Haemostatic function and cardiovascular death: early results of a prospective study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Coagulation factor VII and the risk of coronary heart disease in healthy men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Hemostatic factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

A common genetic polymorphism associated with lower coagulation factor VII levels in healthy individuals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Factor VII coagulant activity and antigen levels in healthy men are determined by interaction between factor VII genotype and plasma triglyceride concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Contribution of Factor VII Genotype to Activated FVII Levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Elevation of factor VII activity and mass in young adults at risk of ischemic heart disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Association between serum fibrinogen concentrations and HDL and LDL subfraction phenotypes in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Association between dietary fat intake and plasma factor VII coagulant activity--a predictor of cardiovascular mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Lipid-thrombosis interface

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Dietary fat induces changes in factor VII coagulant activity through effects on plasma free stearic acid concentration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasma factor VII is activated by postprandial triglyceridaemia, irrespective of dietary fat composition

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Activation of coagulation factor VII during alimentary lipemia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Further evidence that activated factor VII is related to plasma lipids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Epidemiology of coagulation factors, inhibitors and activation markers: The Third Glasgow MONICA Survey. II. Relationships to cardiovascular risk factors and prevalent cardiovascular disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Anticoagulant activity of tissue factor pathway inhibitor in human plasma is preferentially associated with dense subspecies of LDL and HDL and with Lp(a)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Levels of factor VIIc associated with decreased tissue factor pathway inhibitor and increased plasminogen activator inhibitor-1 in dyslipidemias

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Treatment with hydroxymethylglutaryl-coenzyme A reductase inhibitors in hypercholesterolemia induces changes in the components of the extrinsic coagulation system

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Tissue-factor pathway inhibitor and lipoproteins. Evidence for association with and regulation by LDL in human plasma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Moderate weight reduction improves red cell aggregation and factor VII activity in overweight subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinogen and factor VII in the prediction of coronary risk. Results from the PROCAM study in healthy men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Lipoprotein Lp(a) as predictor of myocardial infarction in comparison to fibrinogen, LDL cholesterol and other risk factors: results from the prospective Göttingen Risk Incidence and Prevalence Study (GRIPS).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Association between rheology and components of lipoproteins in human blood. Results from the MONICA project

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Hypobetalipoproteinemia is associated with low levels of hemostatic risk factors in the Framingham offspring population.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Proinsulin, intact insulin, and fibrinolytic variables and fibrinogen in healthy subjects. A population study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Hypertriglyceridemia and regulation of fibrinolytic activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Lipoproteins inhibit the secretion of tissue plasminogen activator from human endothelial cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinolytic activity, clotting factors, and long-term incidence of ischaemic heart disease in the Northwick Park Heart Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinolytic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris. ECAT Study Group. European Concerted Action on Thrombosis and Disabilities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasminogen Activator Inhibitor Type-1 Synthesis and mRNA Expression in HepG2 Cells Are Regulated by VLDL

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Augmentation of synthesis of plasminogen activator inhibitor type-1 in arterial endothelial cells by glucose and its implications for local fibrinolysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Increased synthesis of plasminogen activator inhibitor-1 by cultured human endothelial cells exposed to native and modified LDLs. An LDL receptor-independent phenomenon

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Tissue-type plasminogen activator binds to and is inhibited by surface-bound lipoprotein(a) and low-density lipoprotein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasmin catalyzes binding of lipoprotein (a) to immobilized fibrinogen and fibrin

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

A potential basis for the thrombotic risks associated with lipoprotein(a).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinogen, viscosity and the 10-year incidence of ischaemic heart disease: The Caerphilly and Speedwell Studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasma viscosity and the risk of coronary heart disease: results from the MONICA-Augsburg Cohort Study, 1984 to 1992

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinogen, viscosity, and white blood cell count are major risk factors for ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Plasma viscosity and haematocrit in the course of acute myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Influence of platelet size on outcome after myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Blood viscosity and elevated carotid intima-media thickness in men and women: the Edinburgh Artery Study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Effects of lipoproteins on plasma viscosity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Studies of plasma viscosity in primary hyperlipoproteinaemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

HDL and apolipoprotein A-I protect erythrocytes against the generation of procoagulant activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Antiatherothrombotic properties of statins: implications for cardiovascular event reduction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Treatment of severe hypertriglyceridemia lowers plasma viscosity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Fibrinogen and cardiovascular disease in clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Beneficial effects of statins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Comparison of one-year efficacy and safety of atorvastatin versus lovastatin in primary hypercholesterolemia. Atorvastatin Study Group I.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Atorvastatin: an effective lipid-modifying agent in familial hypercholesterolemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Effect of atorvastatin on plasma fibrinogen

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Lovastatin Alters Blood Rheology in Primary Hyperlipoproteinemia: Dependence on Lipoprotein(a)?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

7 January 2021

Correlation of vitamin K-dependent clotting factors with cholesterol and triglycerides in healthy young adults.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

7 January 2021

Influence of fibrinogen on cardiovascular disease

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

7 January 2021

Lipoprotein(a), fibrin binding, and plasminogen activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0021-9150%2898%2900144-0

7 January 2021

10.1016/S0021-9150(98)00144-0

Identifiers

DOI

1 reference

2 May 2018

1 reference

2 May 2018